- Home
- RLYB vs ASBP Comparison
RLYB vs ASBP Comparison
Compare RLYB & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | ASBP |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 18.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLYB | ASBP |
|---|---|---|
| Price | $0.74 | $0.10 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 176.7K | ★ 56.6M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $674,000.00 | $1,941.00 |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $0.22 | $0.07 |
| 52 Week High | $1.20 | $15.80 |
Technical Indicators
Market Signals| Indicator | RLYB | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 62.81 | 33.53 |
| Support Level | $0.63 | $0.07 |
| Resistance Level | $0.80 | $0.10 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.62 | 55.40 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.